Detecting patterns of atrophy in cognitively impaired individuals using portable, low-field MRI

Comprehensive Summary

The purpose of this research is to determine if low-field magnetic resonance imaging (LF-MRI) together with an AI segmentation analysis tool, is a reliable means of identifying patterns of brain atrophy in people with cognitive impairments. The experiment was conducted with patients undergoing LF-MRI procedures in an outpatient facility with image analysis using an AI segmentation analysis tool (WMH-SynthSeg) to detect volumes in 16 regions of the brain in comparison to high-resolution MRI scanning. The findings indicated a strong correlation between volumes from LF-MRI and high-resolution MRI in relation to all regions (e.g., cortex, white matter, and ventricles) with marked brain atrophy in the cortex, hippocampus, amygdala, putamen, and nucleus accumbens in patients with MCI and AD in comparison to those with vascular comorbidities (VC) (all p < 0.001), with lateral and third ventricular enlargement also indicated in patients with MCI/AD. The article highlights the accuracy of brain volume measurements when using LF-MRI with AI analysis in comparison to conventional MRI and its usability to distinguish between sub-types of dementia through brain atrophy patterns, despite the consistency in white matter hyperintensity volumes being poorer.

Outcomes and Implications

Such a study is significant because it offers a potential avenue towards more readily available measurement of the extent of neurological changes associated with dementia through portable MRI scanning, which may allow for greater availability of neurological scanning for patients regardless of whether or not their health care center has accessible high-quality MRI scanning. In terms of direct application to patients, having such a device available, which measures classical signs of neurological deterioration, such as hippocampal loss in patients with Alzheimer’s, would provide useful information for distinguishing between patients with Alzheimer’s and those with vascular dementia.